Drug Type AAV based gene therapy |
Synonyms AAV9-hPLA2G6, an adeno-associated virus serotype 9 vector expressing the phospholipase PLA2G6 gene (INADcure Foundation) |
Target |
Mechanism PLA2G6 modulators(phospholipase A2 group VI modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroaxonal Dystrophies | Preclinical | US | 29 Nov 2024 |